X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds to fund the ongoing Phase 2 clinical trial of the its product candidate intravesical TARA-002 in patients with high-risk Non-Muscle Invasive Bladder Cancer.
Lead Product(s): TARA-002
Therapeutic Area: Oncology Product Name: TARA-002
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 05, 2024
Details:
IV Choline Chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy initially in development for patients with Choline deficiency receiving parenteral nutrition (PN).
Lead Product(s): Choline Chloride
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
TARA-002, the Company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations.
Lead Product(s): TARA-002
Therapeutic Area: Oncology Product Name: TARA-002
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
TARA-002 is an investigational cell therapy based on the broad immunopotentiator, which is investigated for the treatment of pediatric patients with lymphatic malformations.
Lead Product(s): TARA-002
Therapeutic Area: Oncology Product Name: TARA-002
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration.
Lead Product(s): TARA-002
Therapeutic Area: Oncology Product Name: TARA-002
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
TARA-002 is an investigational cell-based immunopotentiator, which is being investigated for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have carcinoma in situ (CIS).
Lead Product(s): TARA-002
Therapeutic Area: Oncology Product Name: TARA-002
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
TARA-002 is an investigational cell-based immunopotentiator, which is being investigated for the treatment of pediatric patients with lymphatic malformations (LMs).
Lead Product(s): TARA-002
Therapeutic Area: Rare Diseases and Disorders Product Name: TARA-002
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and LMs. When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade.
Lead Product(s): TARA-002
Therapeutic Area: Oncology Product Name: TARA-002
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and LMs for which it has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration.
Lead Product(s): TARA-002
Therapeutic Area: Oncology Product Name: TARA-002
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Data showed OK-432,2, the originator compound for TARA-002 was clinically successful in treating lymphatic malformations and support a favorable safety profile.
Lead Product(s): TARA-002
Therapeutic Area: Rare Diseases and Disorders Product Name: TARA-002
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
